Cytori Therapeutics (CYTX) on Saturday reported that interim results from a European clinical trial, RESTORE 2, demonstrated that cell-enriched breast reconstruction achieved a high rate of patient and physician satisfaction and improvements in overall breast deformity in lumpectomy patients.
The company noted that the results are based on six-month follow up from the first 32 women enrolled and treated.
The highlights from the interim data of Cytori's RESTORE 2 clinical trial includes, a high rate of patient satisfaction and physician satisfaction with the overall outcome after a single treatment was reported in difficult to treat breast cancer patients. The interim data also included mean patient and physician satisfaction scores that dramatically improved for breast symmetry, scarring and deformity from baseline to six month follow-up, and a qualitative analyses of imaging data confirmed clinical improvement in both breast defect and overall breast shape.
RESTORE 2 is a post-marketing study primarily intended to measure patient and physician satisfaction in reconstructing the breast utilizing the Celution 800/CRS System.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.